Sample ForIntel R&D Velocity Audit — Where the Obesity-Drug Race Is Actually Accelerating

What this sample shows

This is a public sample of a ForIntel R&D Velocity Audit deliverable, published by Foragentis to demonstrate the method. It is a field-level read — there is no buyer to redact. The audit studies the GLP-1 / incretin obesity & metabolic therapeutics field as a whole; the developers named in the analysis (Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi) are public-market findings about who is publishing and trialing what, and are preserved in full.

It demonstrates what the audit reads: a structure-and-pace audit built from two directly observed velocity substrates — the scholarly publication record and the clinical-trial registry — cross-corroborated, then joined at the sub-field and organization level into a combined publication × trial ranking of four candidate sub-fields, each carrying an explicit confidence label. The third substrate — patent velocity, normally the leading commercial-R&D indicator — could not be retrieved this run and is carried as a named pending-credential boundary, excluded from the ranking rather than guessed at. Above all, this is structure and pace only: it makes no scientific or clinical claim about any molecule.

The verdict

The obesity-drug field is accelerating fastest in dual / multi-agonists and long-acting injectables; amylin combinations are the emerging watch flag — and two developers anchor it all.

This is an R&D-velocity audit of the GLP-1 / incretin obesity & metabolic field: which sub-fields and which developers are pulling ahead, ranked by the combined publication × trial signal. On the two substrates that returned, the order is clear. Dual / multi-agonists lead — a large, recency-saturated literature (2,548 works) and the deepest trial bench (123 distinct trials, 37 late-phase), with the rise independently corroborated across two literature indexes. Long-acting injectables rank second on the strength of the most late-stage clinical work in the audit (66 of 100 trials at Phase III/IV) — the commercial-stage signal. Oral small-molecule GLP-1 shows the largest raw publication field (7,398) but the lead is partly a broad-search-term artifact, so it ranks third. GLP-1 + amylin is the emerging watch flag: a thin literature (345 works) but a dense, late-phase-heavy trial set concentrated in a single developer (AstraZeneca, 22 trials). Two incumbents — Novo Nordisk and Eli Lilly — anchor the field's sponsor concentration. The principal constraint is that the patent-velocity leg could not be read (a pending credential) and is excluded from the ranking rather than guessed at — named as a boundary, not a finding.

1. Dual & multi-agonists are the field's combined-signal leader — large literature and the deepest trial bench. The dual / multi-agonist sub-field (the GLP-1/GIP and GLP-1/glucagon chemistries) carries a large, recency-saturated publication field (2,548 works on file) and the most total clinical-trial activity of any sub-field — 123 distinct registry records, 37 of them late-phase (III/IV). The two field incumbents (Novo Nordisk, Eli Lilly) lead its sponsor list. The acceleration is independently corroborated: a separate biomedical-literature check on the same sub-field returned a full recent-window batch, all dated to the current year — so the rise is in genuine recent publication dates across two independent indexes, not a single-source artifact. It ranks first on combined publication × trial signal.
2. Long-acting injectables carry the most late-stage clinical momentum — the commercial-stage signal. The long-acting / next-gen injectable sub-field has a comparably large publication field (2,635 works) and, critically, the highest concentration of late-phase work in the audit — 66 of its 100 distinct trials are Phase III/IV. That is where the field's commercial-stage momentum sits, and its sponsor list is led by Eli Lilly and Sanofi. It ranks second on combined signal: slightly behind dual/multi-agonists on total trial breadth, but ahead on late-stage depth — a divergence the ranking names rather than smooths over.
3. Oral small-molecule GLP-1 leads on raw literature volume — but the lead is partly a broad-term artifact. The oral small-molecule sub-field shows the largest raw publication field (7,398 works) and a fully recency-saturated recent sample, with 100 distinct trials (30 late-phase). But the counter-signal pass flags it: that 7,398 rests on the broadest free-text term of the four sub-fields, which over-captures adjacent oral-agent literature, so its publication lead is inflated relative to its true differentiated output. With the patent leg unavailable to disambiguate genuine invention from term breadth, it ranks third — real and accelerating, but not as far ahead as the raw count suggests.
4. GLP-1 + amylin is the emerging watch flag — small literature, but trial-dense and developer-concentrated. The amylin-combination sub-field has by far the smallest publication field (345 works), yet it is disproportionately trial-dense — 90 distinct registry records, 29 of them late-phase. And its trial activity is concentrated in a single emerging developer: AstraZeneca sponsors 22 of the sub-field's trials (and 22 of its 25 field-wide trials sit here). That divergence — thin publications, dense and concentrated trials — is the classic watch-flag shape: rising on one substrate, concentrated in one developer, not yet broadly corroborated. It ranks fourth, as the field's emerging bet rather than its established leader.

In one line: On the substrates that returned — the scholarly publication record and the clinical-trial registry — the GLP-1 obesity field's combined R&D velocity ranks dual / multi-agonists first (largest trial bench, corroborated literature rise), long-acting injectables second (deepest late-stage pipeline), oral small-molecule third (biggest raw literature, but term-inflated), and GLP-1 + amylin fourth as the emerging watch flag (thin literature, dense and AstraZeneca-concentrated trials). Two developers — Novo Nordisk and Eli Lilly — anchor the field. The patent-velocity leg could not be read (a pending credential) and is excluded from the ranking, not guessed at.

How to read this report. This is an R&D-velocity and field-structure read — it reports who is publishing and trialing what, and how fast, and ranks the sub-fields by that combined signal. It makes no scientific or clinical claim about any molecule's safety, efficacy or merit; that is the buyer's call with domain experts. A High confidence chip marks a signal observed across both returned substrates (publication + trial) or independently corroborated; a Medium chip marks a signal that rests on one substrate or a term-breadth caveat, stated inline. Counts are read as floors: the recent-window publication samples are capped and fully saturated by recent work, and trial records are registration-intent signals deduplicated by record (a single program may register more than one). The patent-velocity leg — normally the leading commercial-R&D indicator — could not be retrieved (the patent record needs a credential this run did not carry); it is carried as a pending-credential boundary (closing section) and the combined ranking is computed without it, never fabricated.

01 · Publication velocity — which sub-fields the literature is moving toward

(Confidence: High.) The first velocity substrate is the scholarly publication record — where the research output is accumulating, and how recent it is. Across the four candidate sub-fields the field sizes diverge sharply. Oral small-molecule GLP-1 shows the largest publication field (7,398 works on file), followed by long-acting injectable (2,635) and dual / multi-agonist (2,548), with GLP-1 + amylin far smaller at 345. (Source: the scholarly publication record, per-sub-field match counts.) The recency tell is just as important as the size: for the three larger sub-fields, the most-recent sample we could pull was entirely saturated by recent-window (current-and-prior-year) work — meaning the in-window output exceeds the sample ceiling, so these counts are floors, not a complete census.

Figure — Publication-record field size per sub-field. The three larger sub-fields are recency-saturated (the recent-window sample hits the sample ceiling, so counts are floors). The oral small-molecule total rests on the broadest free-text term and is read with that caveat (Section 04). GLP-1 + amylin is the smallest publication field.

Two reads matter. First, the publication record alone would put oral small-molecule on top — but that headline carries a caveat the counter-signal pass surfaces (Section 04): its field is measured on the broadest search term of the four, which over-captures adjacent oral-agent literature, so the raw lead overstates its differentiated output. Second, an independent biomedical-literature check on the dual / multi-agonist sub-field, run on a different index and restricted to the recent window, returned a full recent-window batch dated entirely to the current year — confirming that sub-field's acceleration is in genuine recent publication dates across two indexes, not a single-indexer back-catalog artifact. One limitation travels with the layer and is named, not buried: these are recent-window floors, and the per-period split is reconstructed from separate dated queries rather than a clean pre-grouped time series.

02 · Trial velocity & phase mix — where the field is moving into the clinic

(Confidence: High.) Publications show where the research is; the clinical-trial registry shows where the field is committing capital and moving into the clinic, and at what stage. Deduplicated on registry record within each sub-field, the trial counts are: dual / multi-agonist 123 distinct trials (the most of any sub-field), oral small-molecule 100, long-acting injectable 100, and GLP-1 + amylin 90. (Source: the clinical-trial registry, per-sub-field record sets, deduplicated.) But the raw count is only half the story — the phase mix tells you how close each sub-field is to commercialization.

Figure — Distinct trial records per sub-field, deduplicated on registry ID, split late-phase (III/IV) vs other. Dual / multi-agonist carries the most total trials; long-acting injectable carries the most late-phase work (66 of 100) — the strongest commercial-stage concentration. Records are registration-intent signals; a single program may register more than one.

The divergence is the signal. Dual / multi-agonists have the broadest bench (123 trials, 37 late-phase) — the widest spread of clinical activity. But long-acting injectables are the most commercially advanced: 66 of their 100 trials are Phase III/IV, the highest late-stage concentration in the audit, which is why they rank second on combined signal despite a slightly smaller total bench. GLP-1 + amylin is the standout for its size: with the smallest publication field, it still fields 90 trials (29 late-phase) — trial-dense relative to its literature, the first tell of an emerging sub-field. One limitation is named: registry records are registration-intent signals (a registered trial is intent, not a guaranteed-completed study), deduplicated by record where the data allows; a single development program may register more than one record, so these are read as pipeline-intent counts, not a program census.

03 · Developer concentration — who is driving the field

(Confidence: High.) The last structural question is which organizations are driving the activity. Across the deduplicated trial set (340 distinct registry records field-wide), the sponsor concentration is led by two familiar incumbents: Novo Nordisk (27 distinct trials) and Eli Lilly (19), with Sanofi (12) and a long tail of biotech and academic sponsors behind them. (Source: the clinical-trial registry, sponsor field across the deduplicated record set.) That two-incumbent structure tracks the publication and trial leadership of the top two sub-fields — the same two organizations that anchor the dual/multi-agonist and long-acting-injectable sponsor lists.

Figure — Leading developers by distinct sponsored trials across the deduplicated registry set. Two incumbents (Novo Nordisk, Eli Lilly) anchor the field; the third-ranked developer (AstraZeneca, 25 trials) is concentrated almost entirely in the amylin-combination sub-field — 22 of its 25 trials — the emerging-developer watch flag. Sponsor naming is imperfectly normalized; one organization may appear under variant names.

The structural surprise sits in third place. AstraZeneca ranks among the most active sponsors in the field (25 distinct trials) — but almost all of that activity is in one sub-field: 22 of its 25 trials are in GLP-1 + amylin. That single-sub-field concentration is exactly why amylin combinations register as the audit's watch flag — a thin publication base but a dense, late-phase-heavy, single-developer-driven trial program. For a buyer, the read is that the amylin opportunity is real and moving but concentrated: it rises or falls largely with one developer's program rather than a broad field consensus. One limitation is named: sponsor names are imperfectly normalized — a single organization can appear under variant legal entities, so the counts are decision-grade for the concentration shape, not for an exact per-entity tally.

04 · The combined-signal ranking — putting the substrates together

(Confidence: High; the oral small-molecule placement carries a Medium term-breadth caveat. Source: the publication × trial join at the sub-field and organization-name level, each call stress-tested against its strongest opposing case.) Combining the two returned velocity substrates — publication and trial — at the sub-field and organization-name level (the defensible join; individual-asset threading is a declared boundary), the ranking falls out cleanly, and each load-bearing call was stress-tested against its strongest opposing case before being named.

Figure — The combined publication × trial ranking of the four candidate sub-fields, with each call's strongest opposing case stated. The order is decision-grade; the absolute velocity gaps are floors that the missing patent leg would sharpen or soften.

One cross-corpus caution governs the whole ranking and is stated plainly: with the patent-velocity leg unavailable, the combined signal rests on two substrates rather than three. Publication and trial activity can share a coverage bias (both lean toward well-indexed, registry-active programs), so the ranking is sound for the relative order of the sub-fields — corroborated where two substrates agree — but the absolute velocity gap between them would be sharper or softer once the patent leg is added. The order is decision-grade; the magnitudes are floors.

05 · What this means for you — where to place a bet, a flag, and a caution

1. Partnership bet — dual / multi-agonists, anchored to the two incumbents. This is the sub-field with the strongest combined velocity: the broadest trial bench, a large and independently-corroborated literature rise, and the field's two leading developers (Novo Nordisk, Eli Lilly) already concentrated in it. For a BD / licensing or investment thesis, it is the highest-confidence, highest-leverage partnership target — the bet supported by the most independent corroboration. Pair the partnership scan with a late-stage overlay from the long-acting-injectable sub-field, which carries the deepest Phase III/IV bench.
2. Watch flag — GLP-1 + amylin, and specifically AstraZeneca's program. The amylin-combination sub-field is rising on the trial substrate (dense, late-phase-heavy) but not yet on publications, and the activity is concentrated in a single developer (22 of the sub-field's trials). That is the textbook watch-flag shape: real momentum, narrow corroboration, single-developer dependence. Track it as an emerging bet to monitor — partnership-worthy if the literature broadens and the concentration diversifies, but premature to treat as an established field consensus today.
3. Caution — do not over-weight the oral small-molecule headline. Oral small-molecule GLP-1 shows the largest raw publication count, which makes it the easy headline pick — but that lead is partly a search-term-breadth artifact, and the patent leg that would confirm genuine differentiated invention is unavailable. Treat it as a genuinely accelerating but over-stated-relative-to-raw-count sub-field: real, but rank it on its trial bench and a disambiguated patent read, not on the headline publication number.
4. Close the patent-velocity gap before sizing the prize. The single most decision-relevant missing input is patent velocity — normally the leading commercial-R&D indicator — which this read could not retrieve (a pending credential). Commission the patent leg before finalizing a partnership valuation: it is the substrate that would disambiguate the oral small-molecule term-breadth question, confirm the leading developers' IP positions, and convert the two-substrate ranking into the full three-substrate combined signal.

Scope, confidence & what a deeper engagement adds

This R&D Velocity Audit reads two velocity substrates — the scholarly publication record and the clinical-trial registry — both directly observed, with the lead sub-field's acceleration corroborated across two literature indexes. The boundaries below are named with the specific reason and the work that closes each. They are diligence boundaries, not findings, and are never presented as such. Above all, this audit reports R&D velocity and field structure only — it makes no scientific or clinical claim about any molecule.

• Patent velocity — a pending-credential boundary (the most consequential gap). The patent record — normally the leading commercial-R&D indicator — returned nothing on every attempt, because the patent-record source requires an access credential this run did not carry; the patent leg was skipped, not searched-and-found-empty. No patent count, assignee ranking or patent-velocity slope is stated or fabricated. The combined ranking is computed on the two substrates that did return (publication + trial), and is sound for the relative order of the sub-fields; the patent leg would sharpen the absolute magnitudes and is the natural first closing move. Closing it: a patent-record pull with a valid credential, for the per-sub-field patent velocity and the assignee-concentration read.
• Velocity period-granularity — reconstructed, not pre-grouped. The publication record does not return counts pre-grouped by period and sub-field, so the per-period velocity was reconstructed from separate dated queries per sub-field and the recent-window samples are capped and saturated — counts are floors, not a complete time series. The direction (which sub-fields are accelerating) is the load-bearing read and is unaffected; the exact slope is bounded. Closing it: uncapped, pre-grouped per-period pulls to quantify the precise velocity curve per sub-field.
• Cross-corpus threading — at the sub-field / organization level, not per-asset. The audit threads the substrates at the sub-field and organization-name level (which developer leads which sub-field across publications and trials) — the defensible join. It does not thread an individual publication to an individual trial to an individual patent via shared identifiers; that chain is thin and lossy and is declared a boundary rather than asserted as a false linkage. Closing it: an identifier-level threading pass once the patent leg is available to complete the chain.
• Trial registry is registration-intent, deduplicated by record. The clinical-trial registry is registration-based — a registered trial is an intent signal, not a guaranteed-completed study — coverage of ex-US trials is uneven, and a single program may register more than one record (inflating raw counts). Counts here are deduplicated by registry record and read as pipeline-intent, not a completed-study or program census. Closing it: a program-level dedup and a status/results overlay to convert intent into completion.
• Structural, not clinical — the deliberate scope. The audit reports who is publishing and trialing what, and how fast. It does not adjudicate which molecule is safer or more efficacious, rank drugs by clinical outcome, or make any medical recommendation. Any scientific, clinical or regulatory interpretation is the buyer's, with domain experts. This is a deliberate tier-scope, not a gap. Closing it: a dedicated clinical / regulatory evidence engagement — a different instrument from this velocity read.

This is a two-substrate R&D-velocity and field-structure read at the R&D Velocity Audit tier. The natural next step is a deeper engagement that completes the picture: (1) the patent-velocity leg with a valid credential — the leading commercial-R&D indicator, which would disambiguate the oral small-molecule term-breadth question and confirm the developers' IP positions; (2) uncapped, pre-grouped per-period pulls for the precise velocity curve per sub-field; and (3) an identifier-level cross-corpus threading pass once the patent leg is in hand. To commission it, reach the ForIntel desk directly at forintel@foragentis.com or scope a subscription on the ForIntel order page.

This is a public sample of a ForIntel R&D Velocity Audit deliverable, published by Foragentis to demonstrate the method. It is a field-level read with no buyer to redact; the developers named (Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi) and the sub-field names are real, public-market findings preserved in full. The publication velocity, the trial velocity and phase mix, and the developer concentration are directly observed, with the lead sub-field's acceleration corroborated across two literature indexes; publication counts are recent-window floors reconstructed from separate dated queries, and trial records are registration-intent signals deduplicated by record. The patent-velocity leg could not be retrieved (a pending access credential) and is carried as a named boundary, not a finding; no patent count or assignee ranking is fabricated. The audit reports R&D velocity and field structure only and makes no scientific or clinical claim about any molecule.